Department of Anesthesiology, Wuhan Third Hospital/Tongren Hospital of Wuhan University, Wuhan, Hubei Province, China.
Kaohsiung J Med Sci. 2024 Feb;40(2):119-130. doi: 10.1002/kjm2.12797. Epub 2024 Jan 19.
Alzheimer's disease (AD) is a progressively debilitating neurodegenerative condition primarily affecting the elderly. Emerging research suggests that microRNAs (miRNAs) play a role in the development of AD. This study investigates the impact of miR-107-5p on neurological damage, oxidative stress, and immune responses in AD. We utilized APP/PS1 mice as AD mouse models and C57BL/6 J mice as controls. AD mice received treatment with agomir miR-107-5p (to overexpress miR-107-5p) or BAY11-7082 (an NF-κB pathway inhibitor). We evaluated learning and memory abilities through the Morris water maze test. Histopathological changes, hippocampal neuron distribution, and apoptosis were assessed using hematoxylin-eosin, Nissl, and TUNEL staining. Reactive oxygen species (ROS) levels, amyloid-Aβ (Aβ1-40/42) contents, and inflammatory factors (TNF-α, IL-6, IL-1β) in hippocampal tissues were measured using ROS kits and enzyme-linked immunosorbent assay (ELISA). Microglial activation in hippocampal tissues was observed under a fluorescence microscope. miR-107-5p's binding to TLR4 was predicted via the TargetScan database and confirmed through a dual-luciferase assay. miR-107-5p expression, along with TLR4, APOE, and TREM2 in hippocampal tissue homogenate, and NF-κB p65 protein expression in the nucleus and cytoplasm were assessed via RT-qPCR and Western blot. Overexpression of miR-107-5p ameliorated hippocampal neurological damage, oxidative stress, and immune responses. This was evidenced by improved enhanced learning/memory abilities, reduced Aβ1-40 and Aβ1-42 levels, diminished neuronal injuries, decreased ROS and TNF-α, IL-6, and IL-1β levels, increased APOE and TREM2 levels, and suppressed microglial activation. miR-107-5p directly targeted and inhibited TLR4 expression, leading to reduced nuclear translocation of NF-κB p65 in the NF-κB pathway. Inhibition of the NF-κB pathway similarly improved neurological damage, oxidative stress, and immune response in AD mice. miR-107-5p exerts its beneficial effects by suppressing the TLR4/NF-κB pathway, ultimately ameliorating neurological damage, oxidative stress, and immune responses in AD mice.
阿尔茨海默病(AD)是一种进行性衰弱的神经退行性疾病,主要影响老年人。新兴研究表明,microRNAs(miRNAs)在 AD 的发展中起作用。本研究探讨了 miR-107-5p 对 AD 中神经损伤、氧化应激和免疫反应的影响。我们使用 APP/PS1 小鼠作为 AD 小鼠模型和 C57BL/6J 小鼠作为对照。AD 小鼠接受 agomir miR-107-5p(过表达 miR-107-5p)或 BAY11-7082(NF-κB 途径抑制剂)治疗。我们通过 Morris 水迷宫试验评估学习和记忆能力。使用苏木精-伊红、尼氏和 TUNEL 染色评估海马神经元分布和细胞凋亡。使用 ROS 试剂盒和酶联免疫吸附试验(ELISA)测量海马组织中的活性氧(ROS)水平、淀粉样蛋白-Aβ(Aβ1-40/42)含量和炎症因子(TNF-α、IL-6、IL-1β)。在荧光显微镜下观察海马组织中的小胶质细胞激活。通过 TargetScan 数据库预测 miR-107-5p 与 TLR4 的结合,并通过双荧光素酶报告基因实验证实。通过 RT-qPCR 和 Western blot 评估海马组织匀浆中 miR-107-5p 的表达以及 TLR4、APOE 和 TREM2,以及核和细胞质中 NF-κB p65 蛋白的表达。miR-107-5p 的过表达改善了海马神经损伤、氧化应激和免疫反应。这表现为学习/记忆能力增强,Aβ1-40 和 Aβ1-42 水平降低,神经元损伤减少,ROS 和 TNF-α、IL-6 和 IL-1β 水平降低,APOE 和 TREM2 水平升高,小胶质细胞激活受到抑制。miR-107-5p 直接靶向并抑制 TLR4 表达,导致 NF-κB 通路中 NF-κB p65 的核转位减少。NF-κB 通路的抑制同样改善了 AD 小鼠的神经损伤、氧化应激和免疫反应。miR-107-5p 通过抑制 TLR4/NF-κB 通路发挥其有益作用,最终改善 AD 小鼠的神经损伤、氧化应激和免疫反应。